Medizinische Universität Graz - Research portal

Navigation/Search

• Researchers.
  • Curriculum.
  • Publications.
  • Presentations.
• Institutions.
• Projects.
• Publications.
• Partners.
• Sponsors.
• Equipment.
• Knowhow.
• Fields of Research.

Apfelbeck Ute |

** = Publications listed in SCI/SSCI/Pubmed

2003

Full paper/article (Journal)

** Kühr, T; Burgstaller, S; Apfelbeck, U; Linkesch, W; Seewann, H; Fridrik, M; Michlmayr, G; Krieger, O; Lutz, D; Lin, W; Pont, J; Köck, L; Abbrederis, K; Baldinger, C; Buder, R; Geissler, D; Hausmaninger, H; Lang, A; Zabernigg, A; Duba, C; Hilbe, W; Eisterer, W; Fiegl, M; Greil, R; Gastl, G; Thaler, J; Austrian CML Study Group A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Leuk Res. 2003; 27(5):405-411 Doi: 10.1016%2FS0145-2126%2802%2900223-0
Web of Science PubMed FullText FullText_MUG

 

Abstract (Journal)

** Kuhr, T; Apfelbeck, U; Linkesch, W; Mistrik, M; Tothova, E; Koza, V; Lutz, D; Vorlieek, J; Cernelc, P; Bernhart, M; Lin, W; Hausmaninger, H; Greil, R; Gastl, G; Michlmayr, G; Thaler, J Treatment of newly-diagnosed CML patients with interferon alpha and continuous versus intermittent cytarabin-ocfosfat (YNK01): A randomized Central European Leukemia Study.
BLOOD 2003 102: 311B-311B.
Web of Science

 

2002

Full paper/article (Journal)

** Beham-Schmid, C; Apfelbeck, U; Sill, H; Tsybrovsky, O; Höfler, G; Haas, OA; Linkesch, W Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.
Blood. 2002; 99(1):381-383 Doi: 10.1182/blood.V99.1.381 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Hilbe, W; Kühr, T; Apfelbeck, U; Fridrik, M; Seewann, H; Stöger, M; Linkesch, W; Pont, J; Baldinger, C; Hartner, E; Bernhart, M; Geissler, D; Krieger, O; Lang, A; Lin, W; Ludwig, H; Duba, C; Greil, R; Gast, G; Thaler, J Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
LEUK LYMPHOMA. 2002; 42(6): 1283-1288. Doi: 10.1080%2F10428190127503
Web of Science PubMed FullText FullText_MUG

 

Abstract (Journal)

** Kuehr, T; Burgstaller, S; Apfelbeck, U; Linkesch, W; Mistrik, M; Tothova, E; Koza, V; Greil, R; Michlmayr, G; Lutz, W; Thaler, J Interferon alpha in combination with intermittent versus continuous YNK01 in patients with CML in early chronic phase: Preliminary results of a randomized phase III study.
BLOOD 2002 100: 328B-328B.
Web of Science

 

2000

Full paper/article (Journal)

** Apfelbeck, U; Hoefler, G; Neumeister, P; Fonatsch, C; Linkesch, W; Sill, H Extramedullary T cell lymphoblastic transformation of chronic myeloid leukaemia successfully treated with matched unrelated donor bone marrow transplantation.
BONE MARROW TRANSPLANT 2000 26: 1111-1112. Doi: 10.1038/sj.bmt.1702665 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Kühr, T; Eisterer, W; Apfelbeck, U; Linkesch, W; Bechter, O; Zabernigg, A; Geissler, K; Barbieri, G; Duba, C; Gastl, G; Thaler, J Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
Leuk Res. 2000; 24(7):583-587 Doi: 10.1016%2FS0145-2126%2800%2900036-9
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Neumeister, P; Strunk, D; Apfelbeck, U; Sill, H; Linkesch, W Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Lancet. 2000; 355(9212):1334-1335 Doi: 10.1016/S0140-6736(00)02120-6 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1997

Full paper/article (Journal)

** Neumeister, P; Hoefler, G; Beham-Schmid, C; Schmidt, H; Apfelbeck, U; Schaider, H; Linkesch, W; Sill, H Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas.
Gastroenterology. 1997; 112(6):1871-1875 Doi: 10.1053%2Fgast.1997.v112.pm9178679
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Thaler, J; Hilbe, W; Apfelbeck, U; Linkesch, W; Sill, H; Seewann, H; Pont, J; Bernhart, M; Stöger, M; Niessner, H; Abbrederis, K; Geissler, D; Hausmaninger, H; Lin, W; Ludwig, H; Lang, A; Duba, C; Fluckinger, T; Greil, R; Grünewald, K; Konwalinka, G; Niederwieser, D; Fridrik, M Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Leuk Res. 1997; 21(1):75-80 Doi: 10.1016%2FS0145-2126%2896%2900084-7
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1996

Abstract (Journal)

** Neumeister, P; Hofler, G; BehamSchmid, C; Schmidt, H; Apfelbeck, U; Linkesch, W; Sill, H Homozygous deletions of the p16 gene in high-grade gastric malt lymphomas.
BLOOD 1996 88: 3311-3311.
Web of Science

 

1994

Full paper/article (Journal)

** Sill, H; Chase, A; Mills, KI; Apfelbeck, U; Sormann, S; Goldman, JM; Cross, NC No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis.
LEUKEMIA. 1994; 8(11): 1923-1928.
Web of Science PubMed

 

** Zweiker, R; Eber, B; Samonigg, H; Reisinger, EC; Kasparek, A; Schumacher, M; Fruhwald, FM; Apfelbeck, U; Klein, W Toxoplasmosis peri-myocarditis as initial manifestation of highly malignant non-Hodgkin's lymphoma
Z Kardiol. 1994; 83(3):234-237 (- Case Report)
Web of Science PubMed

 

↑ Top of page / Navigation

© Med Uni Graz • Imprint